Skip to content

MR Imaging of cerebral blood flow and autoregulation in patients with steno-occlusive vertebro-basilar artery disease.

MR Imaging of cerebral blood flow and autoregulation in patients with steno-occlusive vertebro-basilar artery disease. - VICTOR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36475
Enrollment
80
Registered
2011-05-02
Start date
2012-09-14
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischaemic cerebral stroke

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18 years or older. Patients with ischaemic stroke or TIA in the perfusion territory of the vertebo-basilar arteries. In case of stroke: a clinically stable situation.

Exclusion criteria

Exclusion criteria: Significant and symptomatic stenosis of the carotid arteries. Pregnancy or possible pregnancy. Implanted stent(s). Severe liver or renal dysfunction. Addison*s disease. Allergic reaction for sulfonamides. Cor pulmonale / heart failure (class III-IV) according to the NYHA classification. Longobstruction / emfysema. Primary hyperaldosteronisme. Fenytoïne, primidon and/or fenobarbital use. Japanese and Indian subjects or subjects of Japanese descent. Impossibility to undergo MRI (claustrophobia, metal objects in or around the body).

Design outcomes

Primary

MeasureTime frame
The primary outcome is CVR measured with MR imaging at 3 Tesla using administration of vasodilatory challenge medication to induce hemodynamic stress.

Secondary

MeasureTime frame
Secondary outcomes include cerebral blood flow (CBF) and CVR measured in the visual cortex, and differences in CBF and CVR between the recently symptomatic and asymptomatic patients.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)